Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Immucell (ICCC) Return on Sales (2016 - 2025)

Immucell (ICCC) has disclosed Return on Sales for 16 consecutive years, with 0.03% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Return on Sales rose 10.0% year-over-year to 0.03%, compared with a TTM value of 0.08% through Sep 2025, up 29.0%, and an annual FY2024 reading of 0.08%, up 25.0% over the prior year.
  • Return on Sales was 0.03% for Q3 2025 at Immucell, down from 0.08% in the prior quarter.
  • Across five years, Return on Sales topped out at 0.18% in Q1 2025 and bottomed at 0.67% in Q1 2023.
  • Average Return on Sales over 5 years is 0.13%, with a median of 0.11% recorded in 2021.
  • The sharpest move saw Return on Sales plummeted -76bps in 2023, then skyrocketed 61bps in 2024.
  • Year by year, Return on Sales stood at 0.01% in 2021, then tumbled by -3232bps to 0.43% in 2022, then decreased by -9bps to 0.47% in 2023, then skyrocketed by 114bps to 0.07% in 2024, then crashed by -138bps to 0.03% in 2025.
  • Business Quant data shows Return on Sales for ICCC at 0.03% in Q3 2025, 0.08% in Q2 2025, and 0.18% in Q1 2025.